ARMS Pharmaceutical
ARMS Pharmaceutical, headquartered in Cleveland, Ohio, is focused on developing products targeted at respiratory tract health, a $12 billion market. The company has a strong intellectual property portfolio and is conducting in vitro and clinical studies on its lead drug candidate, ARMS-I, to prevent and treat viral upper respiratory infections. ARMS-I is being evaluated for influenza and COVID-19, with plans to seek FDA approval as a drug for the treatment and/or prevention of vURTIs. The company's approach involves a dual mechanism of a barrier combined with a virucidal agent to prevent and treat infections.
Industries
Nr. of Employees
small (1-50)
ARMS Pharmaceutical
737 Bolivar Rd., Ste. 200, Cleveland, OH 44115
Patents
Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
US-10426761-B2
View DetailsMethod of inhibiting harmful microorganisms and barrier-forming composition therefor
US-10398645-B2
View DetailsMethod of inhibiting harmful microorganisms and barrier-forming composition therefor
US-8992893-B2
View DetailsMethod of inhibiting harmful microorganisms and barrier-forming composition therefor
US-8535646-B2
View Details
Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof
US-10426761-B2
View DetailsMethod of inhibiting harmful microorganisms and barrier-forming composition therefor
US-10398645-B2
View DetailsMethod of inhibiting harmful microorganisms and barrier-forming composition therefor
US-8992893-B2
View DetailsMethod of inhibiting harmful microorganisms and barrier-forming composition therefor
US-8535646-B2
View DetailsProducts
Antiviral oral barrier spray (lead development candidate)
A portable oral spray formulation designed to apply a microbe-impermeable barrier to the oropharynx that is infused with an antiviral agent for first-response prophylaxis and potential early treatment of viral upper respiratory tract infections.
Antiviral oral barrier spray (lead development candidate)
A portable oral spray formulation designed to apply a microbe-impermeable barrier to the oropharynx that is infused with an antiviral agent for first-response prophylaxis and potential early treatment of viral upper respiratory tract infections.
Services
In vitro laboratory testing of candidate formulations against upper respiratory viruses.
Design and conduct of clinical studies for prophylaxis and early treatment of viral upper respiratory tract infections.
Preparation and submission of IND filings and planning for the New Drug regulatory pathway toward approval.
Development and filing of method-of-use and composition patents related to candidate formulations.
In vitro laboratory testing of candidate formulations against upper respiratory viruses.
Design and conduct of clinical studies for prophylaxis and early treatment of viral upper respiratory tract infections.
Preparation and submission of IND filings and planning for the New Drug regulatory pathway toward approval.
Development and filing of method-of-use and composition patents related to candidate formulations.
Expertise Areas
- Clinical trial management
- Preclinical antiviral testing
- Antiviral formulation development (oral/topical spray)
- Barrier-based therapeutic approaches for respiratory mucosa
Key Technologies
- Oral spray drug delivery
- Film-forming/microbe-impermeable barrier technology
- Virucidal antiviral agent incorporation
- In vitro antiviral assay methods